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Abstract
Background: Neuropathic pain is a chronic and intractable symptom associated with nerve injury. The
periaqueductal gray (PAG) is important in the endogenous pain control system and is the main site of the
opioidergic analgesia. To investigate whether neuropathic pain affects the endogenous pain control system, we
examined the effect of neuropathic pain induced by sacral nerve transection on presynaptic GABA release, the
kinetics of postsynaptic GABA-activated Cl
- currents, and the modulatory effect of μ-opioid receptor (MOR)
activation in mechanically isolated PAG neurons with functioning synaptic boutons.
Results: In normal rats, MOR activation inhibited the frequency of GABAergic miniature inhibitory postsynaptic
currents (mIPSCs) to 81.3% of the control without any alteration in their amplitude. In neuropathic rats, the
inhibition of mIPSC frequency by MOR activation was 82.4%. The frequency of GABAergic mIPSCs in neuropathic
rats was 151.8% of normal rats without any difference in the mIPSC amplitude. Analysis of mIPSC kinetics showed
that the fast decay time constant and synaptic charge transfer of mIPSCs in neuropathic rats were 76.0% and
73.2% of normal rats, respectively.
Conclusions: These results indicate that although the inhibitory effect of MOR activation on presynaptic GABA
release is similar in both neuropathic and normal rats, neuropathic pain may inhibit endogenous analgesia in the
PAG through an increase in presynaptic GABA release.
Keywords: Neuropathic pain Endogenous pain control system, Opioid analgesia, GABAergic synaptic transmission,
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Background
Chronic pain can be classified into three categories:
nociceptive pain caused by tissue damage, neuropathic
pain caused by nerve injury, and mixed pain [1]. Patients
with neuropathic pain usually experience abnormal sen-
sations, including allodynia, which is defined as pain in
response to non-nociceptive stimuli and hyperalgesia,
which is defined as increased pain sensitivity to nocicep-
tive stimuli [2]. Although opioid receptor agonists are
the most widely used therapeutic agents for neuropathic
pain, the effectiveness of opioid analgesia is controver-
sial. Several studies have shown that neuropathic pain
can be effectively attenuated by morphine and other μ-
opioid receptor (MOR) agonists [3-10] as well as delta-
opioid agonists [11-14]. By contrast, some studies have
indicated that opioid peptides and morphine do not pos-
sess potent analgesic efficacy against neuropathic pain in
humans [15] and that this ineffectiveness of morphine
can be attributed to a down-regulation of central μ-
opioid transmission [16] and a reduced number of pre-
synaptic opioid receptors due to the degeneration of pri-
mary afferent neurons [17,18].
The midbrain periaqueductal gray (PAG) is believed to
be an important component in the endogenous pain
control system [19]. Several studies have shown that
administration of morphine or opioid peptides, either
systemically or directly into the PAG, produces antinoci-
ception, which is thought to be associated with
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inhibitory interneurons in the PAG are thought to con-
tain GABA as an inhibitory neurotransmitter and inhibit
tonically the output neurons [19,22-25]. Opioid agonists
have been shown to inhibit GABAergic inhibitory synap-
tic input to PAG neurons in rat slice preparations
[24,25]. In previous studies, we have shown that MOR
activation inhibits presynaptic GABA release in acutely
isolated PAG neurons from normal young rats [26].
Although many studies have investigated the analge-
sic effects of opioid agonists on neuropathic pain, it is
not clear whether opioidergic modulation of the endo-
genous pain control system in the PAG is altered by
neuropathic pain. Therefore, in the present study, we
isolated PAG neurons with intact synaptic terminals
from rats with neuropathic pain to examine the effects
of neuropathic pain on presynaptic GABA release, the
kinetics of postsynaptic GABA-activated Cl
- currents,
and the opioid-induced inhibition of GABAergic
synaptic action.
Results
GABAergic mIPSCs in PAG neurons isolated from
neuropathic rats
There were no differences in morphological characteris-
tics between normal and neuropathic rats. Mechanically
dissociated PAG neurons retained short portions of
their proximal dendrites and usually presented an ovoid
soma (approximately 10-20 μm in diameter), although
some neurons presented a triangular soma.
We recorded and measured the mean amplitude and
frequency of mIPSCs 20 min after the rupture of the
patch membrane because it took 10-20 min for synaptic
currents to stabilize (Figure 1). In most neurons, record-
ings of these mIPSCs were stable for approximately 60
min, which indicated that the presynaptic nerve term-
inals attached to the dissociated PAG neurons were
functional and that their spontaneous activity was stable
for at least 60 min. In normal rats, the application of 3
μM bicuculline, a GABAA receptor antagonist, comple-
tely and reversibly blocked mIPSCs (Figure 1A). Reversal
potentials and the slopes of the current-voltage (I-V)
curves were almost identical in both groups. The rever-
sal potential (-5.2 mV for normal rats, -4.9 mV for neu-
ropathic rats) of these mIPSCs, as estimated from the
current-voltage (I-V) relationship, was very similar to
the theoretical Cl
- Nernst equilibrium potential (ECl)o f
-3.5 mV, calculated using extracellular and intracellular
Cl
- concentrations of 161 and 140 mM, respectively
(Figure 1B). The conductance of mIPSCs was 0.924 ±
0.13 μS for normal rats and 0.859 ± 0.11 μSf o rn e u r o -
pathic rats (n =9 ,P = 0.715). These results indicate that
spontaneous mIPSCs in normal rats are mediated by
GABAA receptors.
Effect of MOR activation on GABAergic mIPSCs in
neuropathic rats
In a previous report, we indicated that MOR activation
reduces GABAergic mIPSC in PAG neurons of young
rats [26]. In normal rats, application of 1 μMD A M G O ,
a specific MOR agonist, also reduced the frequency of
GABAergic synaptic events in the majority of PAG neu-
rons tested (61%, 30 of 49 neurons). In the remaining
19 neurons, DAMGO did not significantly alter the fre-
quency or amplitude of mIPSCs. The DAMGO-induced
decrease in mIPSC frequency was reversible (Figure 2)
and could be blocked by pretreatment with 3 μM nalox-
one, a non-specific opioid receptor antagonist (100.5 ±
17.0% of the control, n =3 ,P = 0.981, data not shown).
DAMGO decreased the mIPSC frequency to 81.3 ±
6.4% of the control (Figure 2Ba, Ca; n =4 9 ,P <0 . 0 1 ) ,
but did not alter their amplitude distribution (Figure
2Bb, Cb; 99.4 ± 2.0% of controls, n = 49, P = 0.779).
These data indicate that DAMGO inhibits presynaptic
GABA release via MOR activation at presynaptic term-
inals in PAG neurons of normal rats.
Although statistically not significant, the number of
neurons showing the inhibitory effect of DAMGO on
the frequency of mIPSCs was lower in neuropathic rats
(54%, 19 of 35 neurons) than in normal rats (61%, 30 of
49 neurons; Fisher’s Exact test, P = 0.654). The shape of
these DAMGO-responsive neurons was similar in both
Figure 1 GABAergic spontaneous mIPSCs in PAG neurons
isolated from normal and neuropathic rats. (A) In the presence
of 300 nM TTX, 3 μM CNQX and 10 μM AP5, the application of 3
μM bicuculline completely and reversibly blocked mIPSCs in PAG
neurons isolated from normal rats. The holding voltage (VH) was -60
mV. (B) I-V curve obtained from normal (open circle) and
neuropathic rats (closed circle) for the mean amplitude of mIPSCs
recorded at various VH. Each point is the mean of four neurons. ECl
is the reversal potential of mIPSCs.
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inhibition of mIPSC frequency was also reversible and
could be blocked by pretreatment with 3 μMn a l o x o n e
(data not shown). In neuropathic rats, DAMGO
decreased the frequency of mIPSC to 82.4 ± 4.6% of
controls (Figure 3Ba, Ca; n = 35, P <0 . 0 5 ) ,b u td i dn o t
change the distribution of their amplitudes (Figure 3Bb,
Cb; 102.1 ± 3.5% of controls, n =3 5 ,P = 0.548). The
inhibitory effect of DAMGO on mIPSC frequency was
very similar in the neuropathic and normal rats. These
Figure 2 Inhibitory effect of μ-opioid receptor activation on GABAergic mIPSCs in normal rats. (A) Representative recording trace of
mIPSCs before and during the application of DAMGO (1 μM). (B) Histograms showing cumulative frequency (a) and amplitude distribution (b) of
mIPSCs inhibited by DAMGO. (C) Each column is the mean of 49 neurons. All frequencies (a) and amplitudes (b) are normalized to those of
control mIPSCs.
Figure 3 Inhibitory effect of μ-opioid receptor activation on GABAergic mIPSCs in neuropathic rats. (A) Representative recording trace of
mIPSCs before and during the application of DAMGO (1 μM). (B) Histograms showing the cumulative frequency (a) and amplitude distribution
(b) of mIPSC inhibited by DAMGO. (C) Each column is the mean of 35 neurons. All frequencies (a) and amplitudes (b) were normalized to those
of control mIPSCs.
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inhibitory effect of MOR activation on presynaptic
GABA release in PAG neurons.
Effect of neuropathic pain on presynaptic GABA release
To investigate whether neuropathic pain alters presy-
naptic GABA release in PAG neurons as a mechanism
of hyperalgesia and/or allodynia, we compared the fre-
quencies of presynaptic GABA release in neuropathic
and normal rats. As shown in Figure 4, the frequency of
mIPSCs in neuropathic rats (1.503 ± 0.2 Hz, 151.8% of
the normal rats, n = 35) was higher than that in normal
rats (0.990 ± 0.1 Hz, n = 49; P < 0.05). In the presence
of the inhibitory effect of DAMGO, neuropathic pain
increased the frequency of mIPSCs from 0.616 ± 0.1 Hz
in normal rats (n = 49) to 1.091 ± 0.2 Hz in neuropathic
rats (n = 35, 177.1% of the normal rats; P < 0.05). These
results indicate that neuropathic pain may increase pre-
synaptic GABA release.
Effect of neuropathic pain on the kinetics of postsynaptic
GABA-activated Cl
- channels
To elucidate the effect of neuropathic pain on the
kinetics of postsynaptic GABA-activated Cl
- channels,
the kinetics of GABAergic mIPSCs were analyzed by fit-
ting the currents with two exponential functions and
were then described with time constants (Table 1 and
Figure 5). The 10-90% rise time constant of normal rats
(1.07 ± 0.1 ms) was not different from that of neuro-
pathic rats (0.91 ± 0.1 ms, P =0 . 0 6 6 ,T a b l e1 ) .T h e
weighted mean decay time constant of neuropathic rats
(17.44 ± 0.9 ms) was significantly faster than that of nor-
mal rats (21.03 ± 1.2 ms, P < 0.05). In particular, while
there was no difference between the slow decay time con-
stants (τslow) in both groups (39.89 ± 2.2 ms for normal
rats, 36.64 ± 2.0 ms for neuropathic rats, Table 1), the
fast decay time constant (τfast) of neuropathic rats (8.92 ±
0.4 ms) was faster than that of normal rats (11.74 ± 0.8
ms, P < 0.05, Table 1). Due to the reduced fast decay
time constant, the half-width time of mIPSCs in neuro-
pathic rats could be shortened. Indeed, the half-width
time constant in neuropathic rats (10.29 ± 0.5 ms) was
shorter than that in normal rats (13.29 ± 0.8 ms, P <
0.05, Table 1). In addition, we calculated the area under
the mIPSCs (synaptic charge transfer), which indicates
the integration of the single channel open time and the
duration of the open time of Cl
- channels [27,28]. The
synaptic charge transfer was significantly reduced in neu-
ropathic rats (753.6 ± 42.5 pAms for normal rats, 551.4 ±
35.4 pAms for neuropathic rats, P <0 . 0 5 ,T a b l e1 ,F i g u r e
5). By contrast, MOR activation with DAMGO showed
no effect on mIPSC kinetics in neuropathic rats (Table 1,
Figure 5). These results indicate that neuropathic pain
may promote faster inactivation kinetics of postsynaptic
GABA-activated Cl
- channels.
Discussion
The present study was performed to examine whether
neuropathic pain alters presynaptic GABA release and
postsynaptic GABA-activated Cl
- currents and whether
opioidergic modulation of the GABAergic inhibitory
synaptic response might be affected by neuropathic
pain. Our results show that neuropathic pain increases
the frequency of presynaptic GABA release and
decreases both the fast decay time constant and the
synaptic charge transfer of postsynaptic GABA-activated
Cl
- currents, regardless of whether MOR agonists are
present. In addition, neuropathic pain did not alter the
inhibitory effect of MOR activation on GABAergic
mIPSCs.
Figure 4 Effect of neuropathic pain on presynaptic GABA
release. (A) Histograms comparing the frequency of mIPSCs
between normal and neuropathic rats in the absence of 1 μM
DAMGO. Each column is the mean of 49 neurons. (B) Histograms
comparing the frequency of mIPSCs between normal and
neuropathic rats in the presence of DAMGO. Each column is the
mean of 35 neurons.
Table 1 The kinetics of mIPSC in normal adult and
neuropathic rats
Normal adult Neuropathic
(Mean ± S.E.) (Mean ± S.E.)
Rise 10-90% (ms) Control 1.07 ± 0.1 0.91 ± 0.1
DAMGO 1.10 ± 0.1 0.94 ± 0.0
Decay 90-37% (ms) τfast Control 11.74 ± 0.8 8.92 ± 0.4†
DAMGO 13.32 ± 1.3 9.69 ± 0.6†
τslow Control 39.89 ± 2.2 36.64 ± 2.0
DAMGO 46.50 ± 3.9 36.99 ± 2.5
Weighted mean decay time
(ms)
Control 21.03 ± 1.2 17.44 ± 0.9†
DAMGO 23.55 ± 1.8 18.65 ± 1.0†
Half-width (ms) Control 13.29 ± 0.8 10.29 ± 0.5†
DAMGO 14.66 ± 1.1 11.52 ± 0.6†
Area under currents (pAms) Control 753.6 ± 42.5 551.4 ± 35.4†
DAMGO 897.0 ± 81.4 567.0 ± 39.1†
Values are mean ± S.E. † P < 0.05 for neuropathic rat compared to that of
normal adult rats (Normal adult rat, n = 49 and neuropathic rat, n = 35).
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thy can manifest as severe and intractable pain. How-
ever, the mechanism of this severe and intractable pain
remains unclear. The PAG is an important component
of the endogenous pain control system and is the main
site of the powerful analgesic effects by morphine or
opioid peptides [19]. In a previous report, we suggested
that MOR-induced inhibition of GABAergic inhibitory
synaptic influence in the PAG is the main mechanism of
the opioidergic endogenous pain control system [26]. If
GABAergic synaptic inhibition of PAG neurons is
potentiated by neuropathic pain, this may represent a
potential mechanism of neuropathic pain. Although the
exact mechanisms are not clear, there have been reports
supporting this hypothesis. Activation of the descending
pain control system was shown to be important in the
maintenance of neuropathic pain [29]. The PAG-
mediated inhibition of nociception may be activated by
persistent nociceptive input, possibly reflecting the long-
term changes in the nociceptive circuitry that occur in
neuropathic pain states [30]. In this study, neuropathic
rats showed an increase in the frequency of presynaptic
GABA release in PAG neurons (Figure 4). This finding
indicates that endogenous pain control mechanisms in
t h eP A Gm a yb ei n h i b i t e di na n i m a l ss u f f e r i n gf r o m
neuropathic pain. Thus, this study suggests that neuro-
pathic pain inhibits the efficiency of the endogenous
pain control system in the PAG, thereby inducing severe
and intractable pain.
Although neuropathic pain does not alter the ampli-
tude of postsynaptic GABAergic response, the kinetics
of mIPSC was slightly inhibited in neuropathic rats (Fig-
ure 5, Table 1). Neuropathic rats showed a reduction in
the fast decay time with a reduced half-width time and
synaptic charge transfer of mIPSCs. These findings
might indicate that GABAergic inhibitory input to the
PAG neurons can be decreased in neuropathic rats,
which means that endogenous pain control mechanisms
in the PAG may be activated in neuropathic rats. How-
ever, the decrease in the fast decay time and synaptic
charge transfer of mIPSCs (76.0% and 73.2% of the nor-
mal rats, respectively) was significantly less than the
increase in presynaptic release of GABA (151.8% of the
normal rats, Figure 4). Thus, the changes in mIPSC
kinetics in neuropathic rats may not show a significant
influence to the inhibitory effect of the decreased presy-
naptic GABA release in neuropathic rats on endogenous
pain control mechanisms in the PAG.
Morphine and opioid peptides exert their powerful
analgesic effects through the endogenous pain control
system, especially in the PAG [19]. The efficiency of
opioid receptor agonists, especially the MOR agonist
morphine, has been reported in recent studies of central
and peripheral neuropathic pain disorders [31-34].
Figure 5 Effect of DAMGO on GABAergic mIPSC kinetics in normal and neuropathic rats. (A) Effect of DAMGO on GABAergic mIPSC
kinetics in normal rats. (a) The average current of the control (Control), DAMGO-treated (b), and superimposed (c) mIPSCs in normal rats. There
is no significant difference between control and DAMGO-treated currents. (B) Effect of DAMGO on GABAergic mIPSC kinetics in neuropathic rats.
The control (a) and DAMGO-treated (b) currents of the averaged mIPSCs of neuropathic rats, and the superimposed current of the mIPSCs (c).
There is no significant difference between control and DAMGO-treated currents. (C) Comparison of the kinetics of mIPSC modulated by
neuropathic pain in the presence and absence of DAMGO. The superimposed currents of control (a) and DAMGO-treated (b) mIPSCs in normal
and neuropathic rats.
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such as immunological problems, physical dependency,
and misuse or abuse, is a limitation to the use of opioid
analgesics in patients with neuropathic pain [2]. Further-
more, and the effectiveness of opioid agonists on neuro-
pathic allodynia and hyperalgesia remains controversial.
Several studies have supported the effectiveness of
opioid receptor agonists on neuropathic pain [3-14].
However, some studies have raised questions about the
efficiency of opioid analgesics on neuropathic pain in
humans [15] and animals [16-18,35]. Other studies have
indicated that the PAG is important in opioidergic
analgesia of neuropathic pain. Neuropathic pain that is
induced by peripheral nerve injury has been effectively
alleviated by electrical stimulation of the PAG [36],
microinjection of opioid agonists into the PAG [37], and
supraspinal administration of morphine into the PAG
[9]. Although the analgesic mechanisms have not been
clearly elucidated, these studies suggest that the endo-
genous pain control system, including the PAG, is very
important in the control of neuropathic pain syndrome
and that opioid receptors are involved in this system. In
the present study, MOR agonists inhibited GABAergic
inhibitory synaptic activity in the PAG of neuropathic
rats, and this inhibitory effect of MOR activation was
not significantly different between neuropathic and nor-
mal rats (Figure 2, 3, and 4). Thus, the results of this
study suggest that MOR agonists can effectively exert an
analgesic effect on neuropathic pain through the modu-
lation of the endogenous pain control system in the
PAG and that the analgesic effectiveness of opioid pep-
tides in neuropathic animals is similar to that in normal
animals. However, because neuropathic pain may inhibit
the endogenous pain control mechanism in the PAG in
the resting state (as described above), it is possible that
the analgesic action of exogenous opioid agonists is less
effectively in a neuropathic pain state.
While the majority of proximal dendrites are still
attached to the neurons, the mechanical dissociation can
alter the majority of distal dendrites. Although the
remaining dendritic as well as somatic synapses are well
elucidated to be still functioning [38], it cannot be ruled
out that the dendritic synapses may be modulated in a
different manner shown in the present study.
Conclusions
The results of this study suggest that neuropathic pain
inhibits the endogenous pain control system through an
increase in presynaptic GABA release in the PAG, which
then induces severe and intractable pain. Thus, although
the effect of MOR activation on presynaptic GABA
release in neuropathic rats is similar to that in normal
animals, exogenous opioid agonists may exert their
analgesic actions less effectively in neuropathic rats.
Methods
Animals and surgical procedures
All experimental protocols were approved by the Insti-
tutional Animal Care and Use Committee of the Kyung
Hee University and all efforts were made to minimize
animal suffering and the number of animals utilized.
Male Sprague-Dawley rats (8-12 weeks old) were sub-
jected to a neuropathic pain model, as described in
detail previously [39,40]. In brief, the tail response to a
mechanical stimulus was first tested in all animals prior
to surgery. The rats were restrained in a transparent
plastic tube (5 cm in diameter × 20 cm in length), and
their tails were laid onto a table prior to a behavioral
tail-flicking test. After rats were habituated to the test
environment for 1 h, the mechanical sensitivity of the
tail was determined based on the tail withdrawal
response evoked by the application of a 0.2 g (1.96 mN)
von Frey hair filament. The most sensitive spot of the
tail was first determined for each animal by systemati-
cally rubbing various areas of the tail with the shank of
the von Frey hair; these spots were marked with a sharp
marking pen. Then, each spot was challenged ten times
with the von Frey hair filament at 10- to 20-s intervals.
The occurrence of tail withdrawal in response to the sti-
mulation was expressed as a percentage of trials, which
served as an index of mechanical sensitivity following
peripheral nerve injury. The surgery was performed on
rats that were not responsive to the initial mechanical
stimulation. Each rat was anesthetized with an intraperi-
toneal injection of Zoletil 50
® (50 mg/kg), after which
the left superior caudal trunk was exposed, freed from
the surrounding tissues and transected at the level
between the S3 and S4 spinal nerves. To prevent possi-
ble rejoining of the proximal and distal ends of the sev-
ered trunk, an approximately 1-mm-long section of the
trunk was removed from the proximal end. This surgery
eliminated the S1-S3 spinal nerve innervation of the tail
via the superior caudal trunk. Behavioral tests for signs
of neuropathic pain (mechanical allodynia) were per-
formed at 1 week after surgery. Only rats showing
greater than 80% mechanical allodynia were considered
to conform to the animal model for neuropathic pain.
Isolation of single PAG neurons with synaptic boutons
The mechanical dissociation of single PAG neurons with
functioning synaptic boutons was performed by using
the technique described previously [38,41-43]. In brief,
rats were decapitated under Zoletil 50
® anesthesia (50
mg/kg). The brains were removed, and transverse slices
(350-μm thickness) were made with a microslicer (DTK-
1000, DSK, Kyoto, Japan). Slices were preincubated in
an incubation solution that had been well saturated with
95% O2 and 5% CO2 at room temperature (22-25°C) for
at least 1 h before mechanical dissociation. For
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dish (Primaria 3801; Becton Dickinson, Rutherford, NJ,
USA), and the ventrolateral region of the PAG was iden-
tified under a binocular microscope (SZ-ST, Olympus,
Tokyo, Japan). Mechanical dissociation was performed
using a custom-built vibration device and a fire-polished
glass pipette oscillating at approximately 20-50 Hz (1-2
mm). The tip of the fire-polished glass pipette was
lightly touching the surface of the ventrolateral PAG
region with a micromanipulator and was vibrated hori-
zontally for approximately 2 min. Slices were removed,
and the mechanically dissociated neurons were allowed
to settle and adhere to the bottom of the dish for 15
min. The isolated neurons retained short portions of
their proximal dendrites.
Electrical measurements
Electrical recordings were performed in the conventional
whole-cell patch-clamp recording mode [44] under vol-
tage-clamp conditions at holding potential (VH)o f- 6 0
mV. Patch pipettes were made from borosilicate capil-
lary glass (1.5 mm outer diameter; 1 mm inner diameter;
G-1.5; Narishige, Tokyo, Japan) in two stages on a verti-
cal pipette puller (PP-83; Narishige, Tokyo, Japan). The
resistance of the recording pipettes that were filled with
internal solution was 5-6 MΩ. The patch pipette was
positioned on the neuron using a water-driven micro-
manipulator (WR-60; Narishige, Tokyo, Japan). Neurons
were visualized under phase contrast on an inverted
microscope (IX-70, Olympus, Tokyo, Japan). Electrical
stimulation, voltage control, current recording, and fil-
tration of current (at 1 kHz) were obtained with an
EPC-9 patch-clamp amplifier (EPC-9, HEKA Electronik,
Lambrecht, Germany) linked to a PC controlled by
HEKA software. Current and voltage were monitored
continuously on a computer monitor for the EPC-9
amplifier and displayed on a paper chart linearcorder
(WR3320, Graphtec, Yokohama, Japan). Membrane cur-
rents were digitized at 5 kHz with an ITC 16 board
(HEKA Electronik, Lambrecht, Germany), and stored on
a computer equipped with pCLAMP (version 8.0, Axon
Instruments Inc., Burlingame, CA, USA). During record-
ings, -70 mV hyperpolarizing step pulses (30 ms in
duration) were periodically delivered to monitor access
resistance. All experiments were performed at room
temperature (22-25°C).
Drugs and solutions
Zoletil 50
® (tiletamine HCl 125 mg/5 ml + zolazepam HCl
1 2 5m g / 5m l )w a sp u r c h a s e df r o mV i r b a c( C a r r o s ,
France). Potassium phosphate monobasic, N-2-hydro-
xyethylpiperazine-N’-2-ethanesulfonic acid (HEPES),
dimethyl sulfoxide (DMSO), ethylene glycol-bis (b-ami-
noethylether)-N,N,N’N’-tetraacetic acid (EGTA), tetraethyl
ammonium chloride (TEA), BaCl2, CsCl, magnesium sul-
fate, magnesium chloride, Na-GTP, Mg-ATP, tetrodotoxin
(TTX), 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX),
DL-2-amino-5-phosphonovaleric acid (DL-AP-5), [D-Ala
2,
N-MePhe
4,Gly
5-ol]enkephalin (DAMGO), naloxone HCl,
(-)-bicuculline methochloride, Cs-methanesulfonate and
cadmium chloride were purchased from Sigma Chemical
Co. (St. Louis, MO, USA). CNQX was dissolved in DMSO
at 10 mM as a stock solution. Drugs were added to the
standard external solutions at the final concentrations
indicated in the Result section and the vehicle concentra-
tions never exceeded 0.01%. Drugs were superfused using
a rapid application system termed the “Y-tube method”
that has been described elsewhere [45,46]. The incubation
solution had the following composition (in mM): 124
NaCl, 5 KCl, 1.2 KH2PO4,1 . 3M g S O 4, 2.4 CaCl2,1 0g l u -
cose, and 24 NaHCO3. The pH was adjusted to 7.4 by
continuous bubbling with 95% O2 and 5% CO2. The stan-
dard external solution had the following composition (in
mM): 150 NaCl, 5 KCl, 1 MgCl2, 2 CaCl2, 10 glucose, and
10 N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid
(HEPES). The pH was adjusted to 7.4 with tris-hydroxy-
methylaminomethane (Tris-base). The internal pipette
solution for the recording of miniature inhibitory postsy-
naptic current (mIPSC) had the following ionic composi-
tion (in mM): 110 CsCl, 30 TEA-Cl, 5 EGTA, 5 Mg-ATP,
0.4 Na-GTP, and 10 HEPES. The pH was adjusted to 7.2
with Tris base. To isolate spontaneous mIPSCs, external
solutions routinely contained 300 nM TTX, 1 μM CNQX,
and 10 μM AP-5 to block voltage-dependent Na
+ channels
and glutamatergic excitatory synaptic currents.
Statistical analysis
Spontaneous mIPSCs were analyzed using the MiniAna-
lysis program (Synaptosoft Inc., Leonia, NJ, USA).
Kaleida Graph software (Synergy Software, Reading, PA,
USA) was used for curve fitting. Spontaneous events
were initially detected automatically using an amplitude
threshold of 5 pA (for mIPSC) and then visually
accepted or rejected on the basis of their rise and decay
times. Events with brief rise times (0.5-1.5 ms) and
decay times that were fitted by a single-exponential
function were selected for fast current detection. Aver-
aged current frequency and amplitude were normalized
to the control conditions and were provided as means ±
S.E.M. Differences in current amplitude and frequency
between each single neuron were tested with Student’s
paired two-tailed t-test using absolute values. Fisher’s
Exact test was performed to see if there was a contin-
gency between the two kinds of classification. Difference
in amplitude distributions of miniature currents
obtained from a single neuron were examined by con-
structing all-point cumulative probability distributions
a n dc o m p a r e du s i n gt h eK o l m o g o r o v - S m i r n o v( K - S )
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Page 7 of 9test. Values of P < 0.05 were considered significant. The
mIPSC kinetics were fitted by two exponential functions
for further detailed analysis and were described as their
decay phases with time constants and area under the
current. The weighted mean decay time constant (τm)
was calculated as τm =( A fast×τfast +A slow×τslow)/(Afast
+Aslow), where τfast and τslow are the respective time con-
stants, and Afast and Aslow are the current amplitude
constants. Each parameter was compared using Stu-
dent’sp a i r e dt w o - t a i l e dt-test. Values of P <0 . 0 5w e r e
considered significant.
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